English

INOVIO PHARMACEUTICALS, INC.

EDGAR

INO Quarterly report (10-Q) · filed 2026-08-12

Annual consolidated revenue for 2025: about USD 65.34K, using the latest reported figures. The previous period, 2024, was about USD 217.8K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-18 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -39638543 USD Source
Operating Cash Flow: -21591316 USD Source

Free cash flow

-18 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -39638543 USD Source
Operating Cash Flow: -21591316 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 31.5 million USD 2026-06-30 Source
Exact value

31526164 USD
Long-term debt including current maturities: 62.8 million USD 2019-06-30 Source
Exact value

62757286 USD
Shares outstanding: 82.3 million shares 2026-06-30 Source
Exact value

82341945 shares

Reported share-count change

124.25% · 45.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

36718527 shares · 2025-06-30· Source
82341945 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 65343 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 65343 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-67.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -45496672 USD · 2025-07-01 – 2025-09-30 Source
Net income: -84945901 USD · 2025-01-01 – 2025-12-31 Source
Net income: -88710781 USD · 2025-01-01 – 2025-09-30 Source
Net income: -19682798 USD · 2026-01-01 – 2026-03-31 Source
Net income: -6012458 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-80.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -69258881 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -47685386 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -88629430 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -69258881 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21591316 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -39638543 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21591316 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

195 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 158254 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 90303 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 285698 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 158254 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-80.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -69258881 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -47685386 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -88629430 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -69258881 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21591316 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -39638543 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21591316 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 158254 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 90303 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 285698 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 158254 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2018-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-70%

Prior period

USD 217,756

2024-01-01 – 2024-12-31
Current period

USD 65,343

2025-01-01 – 2025-12-31

Exact inputs and evidence

65343 − 217756 = -152413 USD

217756 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
65343 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Year-over-year change in Revenue: -152413 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 65343 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1040719 Filing: 000105572626000008 Input fundies:Revenue: 217756 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1041524 Filing: 000105572626000008
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 22.31 million

Prior period

−USD 107.25 million

2024-01-01 – 2024-12-31
Current period

−USD 84.95 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-84945901 − -107254126 = 22308225 USD

-107254126 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-84945901 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Year-over-year change in Net income: 22308225 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -84945901 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1384295 Filing: 000105572626000008 Input fundies:NetIncome: -107254126 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1385071 Filing: 000105572626000008
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 15.45 million

Prior period

−USD 104.08 million

2024-01-01 – 2024-12-31
Current period

−USD 88.63 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-88629430 − -104076553 = 15447123 USD

-104076553 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-88629430 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Year-over-year change in Operating cash flow: 15447123 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -88629430 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1293211 Filing: 000105572626000008 Input fundies:OperatingCashFlow: -104076553 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1293865 Filing: 000105572626000008
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-41.4%

Prior period

USD 487,832

2024-01-01 – 2024-12-31
Current period

USD 285,698

2025-01-01 – 2025-12-31

Exact inputs and evidence

285698 − 487832 = -202134 USD

487832 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
285698 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Year-over-year change in Capital expenditure: -202134 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 285698 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1299787 Filing: 000105572626000008 Input fundies:CapitalExpenditure: 487832 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1300377 Filing: 000105572626000008
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 65,343 100% of revenue
Operating costs Derived USD 86.89 million 132,971% of revenue
Operating income −USD 86.82 million −132,871% of revenue
Tax, interest and other Derived −USD 1.88 million −2,871% of revenue
Net income −USD 84.95 million −130,000% of revenue

Cash

Operating cash flow −USD 88.63 million −135,637% of revenue
Capital expenditure USD 285,698 437% of revenue
Free cash flow Derived −USD 88.92 million −136,074% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 316% of revenue.
2017 Operating loss: operating costs were 298% of revenue.
2018 Operating loss: operating costs were 409% of revenue.
2019 Operating loss: operating costs were 2,802% of revenue.
2020 Operating loss: operating costs were 1,774% of revenue.
2021 Operating loss: operating costs were 17,072% of revenue.
2022 Operating loss: operating costs were 2,707% of revenue.
2023 Operating loss: operating costs were 17,400% of revenue.
2024 Operating loss: operating costs were 51,717% of revenue.
2025 Operating loss: operating costs were 132,971% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	35368361	111604298 Derived	-76235937	-2495598 Derived	-73740339	-65293522 Derived	Source 2016-01-01 – 2016-12-31: 35368361 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -76235937 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -73740339 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -62555052 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2738470 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	42220086	125862987 Derived	-83642901	4562871 Derived	-88205772	-73502823 Derived	Source 2017-01-01 – 2017-12-31: 42220086 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -83642901 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -88205772 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -63208921 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 10293902 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	30481897	124573035 Derived	-94091138	2876692 Derived	-96967830	-75635178 Derived	Source 2018-01-01 – 2018-12-31: 30481897 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -94091138 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -96967830 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -73550156 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2085022 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	4111930	115220475 Derived	-111108545	8250674 Derived	-119359219	-98838062 Derived	Source 2019-01-01 – 2019-12-31: 4111930 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -111108545 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -119359219 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -97850136 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 987926 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	7411220	131493264 Derived	-124082044	42329113 Derived	-166411157	-179499711 Derived	Source 2020-01-01 – 2020-12-31: 7411220 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -124082044 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -166411157 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -177979046 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1520665 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1774758	302992677 Derived	-301217919	2440791 Derived	-303658710	-216939531 Derived	Source 2021-01-01 – 2021-12-31: 1774758 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -301217919 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -303658710 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -215708525 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1231006 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	10262268	277835788 Derived	-267573520	12244545 Derived	-279818065	-217184574 Derived	Source 2022-01-01 – 2022-12-31: 10262268 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -267573520 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -279818065 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -216215421 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 969153 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	832010	144772038 Derived	-143940028	-8822676 Derived	-135117352	-124686449 Derived	Source 2023-01-01 – 2023-12-31: 832010 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -143940028 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -135117352 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -124365551 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 320898 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	217756	112616678 Derived	-112398922	-5144796 Derived	-107254126	-104564385 Derived	Source 2024-01-01 – 2024-12-31: 217756 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -112398922 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -107254126 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -104076553 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 487832 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	65343	86887447 Derived	-86822104	-1876203 Derived	-84945901	-88915128 Derived	Source 2025-01-01 – 2025-12-31: 65343 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -86822104 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -84945901 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -88629430 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 285698 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 65.3K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	35368361	Revenue: 35368361 Open source
20172017-12-31	Revenue	42220086	Revenue: 42220086 Open source
20182018-12-31	Revenue	30481897	Revenue: 30481897 Open source
20192019-12-31	Revenue	4111930	Revenue: 4111930 Open source
20202020-12-31	Revenue	7411220	Revenue: 7411220 Open source
20212021-12-31	Revenue	1774758	Revenue: 1774758 Open source
20222022-12-31	Revenue	10262268	Revenue: 10262268 Open source
20232023-12-31	Revenue	832010	Revenue: 832010 Open source
20242024-12-31	Revenue	217756	Revenue: 217756 Open source
20252025-12-31	Revenue	65343	Revenue: 65343 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-70% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-12.8%	Revenue: 35368361 Open source Revenue: 40572111 Open source
20172017-12-31	Year over year	19.4%	Revenue: 42220086 Open source Revenue: 35368361 Open source
20182018-12-31	Year over year	-27.8%	Revenue: 30481897 Open source Revenue: 42220086 Open source
20192019-12-31	Year over year	-86.5%	Revenue: 4111930 Open source Revenue: 30481897 Open source
20202020-12-31	Year over year	80.2%	Revenue: 7411220 Open source Revenue: 4111930 Open source
20212021-12-31	Year over year	-76.1%	Revenue: 1774758 Open source Revenue: 7411220 Open source
20222022-12-31	Year over year	478.2%	Revenue: 10262268 Open source Revenue: 1774758 Open source
20232023-12-31	Year over year	-91.9%	Revenue: 832010 Open source Revenue: 10262268 Open source
20242024-12-31	Year over year	-73.8%	Revenue: 217756 Open source Revenue: 832010 Open source
20252025-12-31	Year over year	-70%	Revenue: 65343 Open source Revenue: 217756 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -132,871.3% 2025

Net margin -130,000% 2025

Free cash flow margin -136,074.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-215.5%	Operating Income: -76235937 Open source Revenue: 35368361 Open source
20172017-12-31	Operating margin	-198.1%	Operating Income: -83642901 Open source Revenue: 42220086 Open source
20182018-12-31	Operating margin	-308.7%	Operating Income: -94091138 Open source Revenue: 30481897 Open source
20192019-12-31	Operating margin	-2,702.1%	Operating Income: -111108545 Open source Revenue: 4111930 Open source
20202020-12-31	Operating margin	-1,674.2%	Operating Income: -124082044 Open source Revenue: 7411220 Open source
20212021-12-31	Operating margin	-16,972.3%	Operating Income: -301217919 Open source Revenue: 1774758 Open source
20222022-12-31	Operating margin	-2,607.4%	Operating Income: -267573520 Open source Revenue: 10262268 Open source
20232023-12-31	Operating margin	-17,300.3%	Operating Income: -143940028 Open source Revenue: 832010 Open source
20242024-12-31	Operating margin	-51,616.9%	Operating Income: -112398922 Open source Revenue: 217756 Open source
20252025-12-31	Operating margin	-132,871.3%	Operating Income: -86822104 Open source Revenue: 65343 Open source
20162016-12-31	Net margin	-208.5%	Net Income: -73740339 Open source Revenue: 35368361 Open source
20172017-12-31	Net margin	-208.9%	Net Income: -88205772 Open source Revenue: 42220086 Open source
20182018-12-31	Net margin	-318.1%	Net Income: -96967830 Open source Revenue: 30481897 Open source
20192019-12-31	Net margin	-2,902.8%	Net Income: -119359219 Open source Revenue: 4111930 Open source
20202020-12-31	Net margin	-2,245.4%	Net Income: -166411157 Open source Revenue: 7411220 Open source
20212021-12-31	Net margin	-17,109.9%	Net Income: -303658710 Open source Revenue: 1774758 Open source
20222022-12-31	Net margin	-2,726.7%	Net Income: -279818065 Open source Revenue: 10262268 Open source
20232023-12-31	Net margin	-16,239.9%	Net Income: -135117352 Open source Revenue: 832010 Open source
20242024-12-31	Net margin	-49,254.3%	Net Income: -107254126 Open source Revenue: 217756 Open source
20252025-12-31	Net margin	-130,000%	Net Income: -84945901 Open source Revenue: 65343 Open source
20162016-12-31	Free cash flow margin	-184.6%	Revenue: 35368361 Open source Operating Cash Flow: -62555052 Open source Capital Expenditure: 2738470 Open source
20172017-12-31	Free cash flow margin	-174.1%	Revenue: 42220086 Open source Operating Cash Flow: -63208921 Open source Capital Expenditure: 10293902 Open source
20182018-12-31	Free cash flow margin	-248.1%	Revenue: 30481897 Open source Operating Cash Flow: -73550156 Open source Capital Expenditure: 2085022 Open source
20192019-12-31	Free cash flow margin	-2,403.7%	Revenue: 4111930 Open source Operating Cash Flow: -97850136 Open source Capital Expenditure: 987926 Open source
20202020-12-31	Free cash flow margin	-2,422%	Revenue: 7411220 Open source Operating Cash Flow: -177979046 Open source Capital Expenditure: 1520665 Open source
20212021-12-31	Free cash flow margin	-12,223.6%	Revenue: 1774758 Open source Operating Cash Flow: -215708525 Open source Capital Expenditure: 1231006 Open source
20222022-12-31	Free cash flow margin	-2,116.3%	Revenue: 10262268 Open source Operating Cash Flow: -216215421 Open source Capital Expenditure: 969153 Open source
20232023-12-31	Free cash flow margin	-14,986.2%	Revenue: 832010 Open source Operating Cash Flow: -124365551 Open source Capital Expenditure: 320898 Open source
20242024-12-31	Free cash flow margin	-48,019.1%	Revenue: 217756 Open source Operating Cash Flow: -104076553 Open source Capital Expenditure: 487832 Open source
20252025-12-31	Free cash flow margin	-136,074.5%	Revenue: 65343 Open source Operating Cash Flow: -88629430 Open source Capital Expenditure: 285698 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -88.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-62555052	Operating Cash Flow: -62555052 Open source
20172017-12-31	Operating cash flow	-63208921	Operating Cash Flow: -63208921 Open source
20182018-12-31	Operating cash flow	-73550156	Operating Cash Flow: -73550156 Open source
20192019-12-31	Operating cash flow	-97850136	Operating Cash Flow: -97850136 Open source
20202020-12-31	Operating cash flow	-177979046	Operating Cash Flow: -177979046 Open source
20212021-12-31	Operating cash flow	-215708525	Operating Cash Flow: -215708525 Open source
20222022-12-31	Operating cash flow	-216215421	Operating Cash Flow: -216215421 Open source
20232023-12-31	Operating cash flow	-124365551	Operating Cash Flow: -124365551 Open source
20242024-12-31	Operating cash flow	-104076553	Operating Cash Flow: -104076553 Open source
20252025-12-31	Operating cash flow	-88629430	Operating Cash Flow: -88629430 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -88.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-65293522	Operating Cash Flow: -62555052 Open source Capital Expenditure: 2738470 Open source
20172017-12-31	Free cash flow	-73502823	Operating Cash Flow: -63208921 Open source Capital Expenditure: 10293902 Open source
20182018-12-31	Free cash flow	-75635178	Operating Cash Flow: -73550156 Open source Capital Expenditure: 2085022 Open source
20192019-12-31	Free cash flow	-98838062	Operating Cash Flow: -97850136 Open source Capital Expenditure: 987926 Open source
20202020-12-31	Free cash flow	-179499711	Operating Cash Flow: -177979046 Open source Capital Expenditure: 1520665 Open source
20212021-12-31	Free cash flow	-216939531	Operating Cash Flow: -215708525 Open source Capital Expenditure: 1231006 Open source
20222022-12-31	Free cash flow	-217184574	Operating Cash Flow: -216215421 Open source Capital Expenditure: 969153 Open source
20232023-12-31	Free cash flow	-124686449	Operating Cash Flow: -124365551 Open source Capital Expenditure: 320898 Open source
20242024-12-31	Free cash flow	-104564385	Operating Cash Flow: -104076553 Open source Capital Expenditure: 487832 Open source
20252025-12-31	Free cash flow	-88915128	Operating Cash Flow: -88629430 Open source Capital Expenditure: 285698 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

67.6% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	29%	Total Liabilities: 50328746 Open source Total Assets: 173707166 Open source
20172017-12-31	Liabilities / assets	23.9%	Total Liabilities: 44750461 Open source Total Assets: 187239270 Open source
20182018-12-31	Liabilities / assets	33.6%	Total Liabilities: 44080858 Open source Total Assets: 131113265 Open source
20192019-12-31	Liabilities / assets	96.2%	Total Liabilities: 138546739 Open source Total Assets: 143951597 Open source
20202020-12-31	Liabilities / assets	14.6%	Total Liabilities: 78631714 Open source Total Assets: 539772472 Open source
20212021-12-31	Liabilities / assets	19.4%	Total Liabilities: 96272072 Open source Total Assets: 495941493 Open source
20222022-12-31	Liabilities / assets	36.2%	Total Liabilities: 126170546 Open source Total Assets: 348533302 Open source
20232023-12-31	Liabilities / assets	31.4%	Total Liabilities: 53602294 Open source Total Assets: 170951423 Open source
20242024-12-31	Liabilities / assets	39.5%	Total Liabilities: 44693411 Open source Total Assets: 113197206 Open source
20252025-12-31	Liabilities / assets	67.6%	Total Liabilities: 50213759 Open source Total Assets: 74310035 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.4× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	2.84×	Current Assets: 124597233 Open source Current Liabilities: 43823027 Open source
20172017-12-31	Current assets / current liabilities	3.91×	Current Assets: 138362160 Open source Current Liabilities: 35405426 Open source
20182018-12-31	Current assets / current liabilities	2.49×	Current Assets: 87814824 Open source Current Liabilities: 35299759 Open source
20192019-12-31	Current assets / current liabilities	2.94×	Current Assets: 94200969 Open source Current Liabilities: 31989321 Open source
20202020-12-31	Current assets / current liabilities	11.3×	Current Assets: 471170690 Open source Current Liabilities: 41705954 Open source
20212021-12-31	Current assets / current liabilities	6.82×	Current Assets: 448444945 Open source Current Liabilities: 65741633 Open source
20222022-12-31	Current assets / current liabilities	3.25×	Current Assets: 315242680 Open source Current Liabilities: 96868074 Open source
20232023-12-31	Current assets / current liabilities	3.6×	Current Assets: 153113100 Open source Current Liabilities: 42570228 Open source
20242024-12-31	Current assets / current liabilities	2.77×	Current Assets: 97830050 Open source Current Liabilities: 35325584 Open source
20252025-12-31	Current assets / current liabilities	1.4×	Current Assets: 61123346 Open source Current Liabilities: 43668555 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 73.74 million Exact value Exact value: -73740339 USD 2016-01-01 – 2016-12-31: -73740339 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2016-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -73740339 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73740339 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572619000012/ino-20181231.xml#478210 Filing: 000105572619000012 The citation records this snapshot. The page link may show a newer release later.	−USD 62.56 million Exact value Exact value: -62555052 USD 2016-01-01 – 2016-12-31: -62555052 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2016-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -62555052 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -62555052 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572619000012/ino-20181231.xml#477577 Filing: 000105572619000012 The citation records this snapshot. The page link may show a newer release later.	USD 2.74 million Exact value Exact value: 2738470 USD 2016-01-01 – 2016-12-31: 2738470 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2016-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 2738470 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2738470 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572619000012/ino-20181231.xml#491824 Filing: 000105572619000012 The citation records this snapshot. The page link may show a newer release later.	−USD 65.29 million Calculation and evidence -62555052 − 2738470 USD Exact free cash flow: -65293522 USD 2016-01-01 – 2016-12-31: -62555052 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2738470 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2016-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -65293522 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -62555052 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572619000012/ino-20181231.xml#477577 Filing: 000105572619000012 Input fundies:CapitalExpenditure: 2738470 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572619000012/ino-20181231.xml#491824 Filing: 000105572619000012 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 88.21 million Exact value Exact value: -88205772 USD 2017-01-01 – 2017-12-31: -88205772 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2017-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -88205772 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -88205772 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-20191231.xml#460971 Filing: 000105572620000012 The citation records this snapshot. The page link may show a newer release later.	−USD 63.21 million Exact value Exact value: -63208921 USD 2017-01-01 – 2017-12-31: -63208921 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2017-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -63208921 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63208921 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-20191231.xml#460338 Filing: 000105572620000012 The citation records this snapshot. The page link may show a newer release later.	USD 10.29 million Exact value Exact value: 10293902 USD 2017-01-01 – 2017-12-31: 10293902 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2017-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 10293902 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10293902 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-20191231.xml#480586 Filing: 000105572620000012 The citation records this snapshot. The page link may show a newer release later.	−USD 73.5 million Calculation and evidence -63208921 − 10293902 USD Exact free cash flow: -73502823 USD 2017-01-01 – 2017-12-31: -63208921 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 10293902 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2017-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -73502823 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63208921 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-20191231.xml#460338 Filing: 000105572620000012 Input fundies:CapitalExpenditure: 10293902 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-20191231.xml#480586 Filing: 000105572620000012 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 96.97 million Exact value Exact value: -96967830 USD 2018-01-01 – 2018-12-31: -96967830 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2018-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -96967830 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -96967830 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572621000018/ino-20201231.htm#1544992 Filing: 000105572621000018 The citation records this snapshot. The page link may show a newer release later.	−USD 73.55 million Exact value Exact value: -73550156 USD 2018-01-01 – 2018-12-31: -73550156 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2018-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -73550156 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73550156 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572621000018/ino-20201231.htm#1961339 Filing: 000105572621000018 The citation records this snapshot. The page link may show a newer release later.	USD 2.09 million Exact value Exact value: 2085022 USD 2018-01-01 – 2018-12-31: 2085022 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2018-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 2085022 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2085022 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572621000018/ino-20201231.htm#1971533 Filing: 000105572621000018 The citation records this snapshot. The page link may show a newer release later.	−USD 75.64 million Calculation and evidence -73550156 − 2085022 USD Exact free cash flow: -75635178 USD 2018-01-01 – 2018-12-31: -73550156 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2085022 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2018-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -75635178 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -73550156 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572621000018/ino-20201231.htm#1961339 Filing: 000105572621000018 Input fundies:CapitalExpenditure: 2085022 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572621000018/ino-20201231.htm#1971533 Filing: 000105572621000018 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 119.36 million Exact value Exact value: -119359219 USD 2019-01-01 – 2019-12-31: -119359219 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2019-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -119359219 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -119359219 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572622000008/ino-20211231.htm#1351917 Filing: 000105572622000008 The citation records this snapshot. The page link may show a newer release later.	−USD 97.85 million Exact value Exact value: -97850136 USD 2019-01-01 – 2019-12-31: -97850136 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2019-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -97850136 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -97850136 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572622000008/ino-20211231.htm#1777774 Filing: 000105572622000008 The citation records this snapshot. The page link may show a newer release later.	USD 987,926 Exact value Exact value: 987926 USD 2019-01-01 – 2019-12-31: 987926 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2019-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 987926 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 987926 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572622000008/ino-20211231.htm#1788034 Filing: 000105572622000008 The citation records this snapshot. The page link may show a newer release later.	−USD 98.84 million Calculation and evidence -97850136 − 987926 USD Exact free cash flow: -98838062 USD 2019-01-01 – 2019-12-31: -97850136 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 987926 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2019-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -98838062 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -97850136 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572622000008/ino-20211231.htm#1777774 Filing: 000105572622000008 Input fundies:CapitalExpenditure: 987926 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572622000008/ino-20211231.htm#1788034 Filing: 000105572622000008 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 166.41 million Exact value Exact value: -166411157 USD 2020-01-01 – 2020-12-31: -166411157 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2020-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -166411157 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -166411157 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572623000010/ino-20221231.htm#1251946 Filing: 000105572623000010 The citation records this snapshot. The page link may show a newer release later.	−USD 177.98 million Exact value Exact value: -177979046 USD 2020-01-01 – 2020-12-31: -177979046 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2020-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -177979046 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -177979046 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572623000010/ino-20221231.htm#1666028 Filing: 000105572623000010 The citation records this snapshot. The page link may show a newer release later.	USD 1.52 million Exact value Exact value: 1520665 USD 2020-01-01 – 2020-12-31: 1520665 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2020-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 1520665 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1520665 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572623000010/ino-20221231.htm#1676288 Filing: 000105572623000010 The citation records this snapshot. The page link may show a newer release later.	−USD 179.5 million Calculation and evidence -177979046 − 1520665 USD Exact free cash flow: -179499711 USD 2020-01-01 – 2020-12-31: -177979046 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1520665 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2020-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -179499711 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -177979046 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572623000010/ino-20221231.htm#1666028 Filing: 000105572623000010 Input fundies:CapitalExpenditure: 1520665 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572623000010/ino-20221231.htm#1676288 Filing: 000105572623000010 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 303.66 million Exact value Exact value: -303658710 USD 2021-01-01 – 2021-12-31: -303658710 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2021-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -303658710 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -303658710 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1357459 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.	−USD 215.71 million Exact value Exact value: -215708525 USD 2021-01-01 – 2021-12-31: -215708525 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2021-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -215708525 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -215708525 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1415443 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.	USD 1.23 million Exact value Exact value: 1231006 USD 2021-01-01 – 2021-12-31: 1231006 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2021-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 1231006 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1231006 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1422151 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.	−USD 216.94 million Calculation and evidence -215708525 − 1231006 USD Exact free cash flow: -216939531 USD 2021-01-01 – 2021-12-31: -215708525 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1231006 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2021-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -216939531 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -215708525 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1415443 Filing: 000105572624000011 Input fundies:CapitalExpenditure: 1231006 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1422151 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 279.82 million Exact value Exact value: -279818065 USD 2022-01-01 – 2022-12-31: -279818065 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2022-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -279818065 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -279818065 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1356673 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.	−USD 216.22 million Exact value Exact value: -216215421 USD 2022-01-01 – 2022-12-31: -216215421 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2022-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -216215421 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -216215421 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1414776 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.	USD 969,153 Exact value Exact value: 969153 USD 2022-01-01 – 2022-12-31: 969153 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2022-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 969153 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 969153 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1421555 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.	−USD 217.18 million Calculation and evidence -216215421 − 969153 USD Exact free cash flow: -217184574 USD 2022-01-01 – 2022-12-31: -216215421 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 969153 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2022-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -217184574 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -216215421 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1414776 Filing: 000105572624000011 Input fundies:CapitalExpenditure: 969153 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm#1421555 Filing: 000105572624000011 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 135.12 million Exact value Exact value: -135117352 USD 2023-01-01 – 2023-12-31: -135117352 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2023-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -135117352 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -135117352 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000012/ino-20241231.htm#1396574 Filing: 000105572625000012 The citation records this snapshot. The page link may show a newer release later.	−USD 124.37 million Exact value Exact value: -124365551 USD 2023-01-01 – 2023-12-31: -124365551 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2023-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -124365551 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -124365551 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000012/ino-20241231.htm#1308355 Filing: 000105572625000012 The citation records this snapshot. The page link may show a newer release later.	USD 320,898 Exact value Exact value: 320898 USD 2023-01-01 – 2023-12-31: 320898 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2023-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 320898 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 320898 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000012/ino-20241231.htm#1313415 Filing: 000105572625000012 The citation records this snapshot. The page link may show a newer release later.	−USD 124.69 million Calculation and evidence -124365551 − 320898 USD Exact free cash flow: -124686449 USD 2023-01-01 – 2023-12-31: -124365551 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 320898 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2023-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -124686449 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -124365551 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000012/ino-20241231.htm#1308355 Filing: 000105572625000012 Input fundies:CapitalExpenditure: 320898 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000012/ino-20241231.htm#1313415 Filing: 000105572625000012 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 107.25 million Exact value Exact value: -107254126 USD 2024-01-01 – 2024-12-31: -107254126 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2024-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -107254126 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -107254126 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1385071 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 104.08 million Exact value Exact value: -104076553 USD 2024-01-01 – 2024-12-31: -104076553 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2024-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -104076553 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -104076553 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1293865 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.	USD 487,832 Exact value Exact value: 487832 USD 2024-01-01 – 2024-12-31: 487832 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2024-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 487832 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 487832 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1300377 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 104.56 million Calculation and evidence -104076553 − 487832 USD Exact free cash flow: -104564385 USD 2024-01-01 – 2024-12-31: -104076553 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 487832 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2024-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -104564385 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -104076553 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1293865 Filing: 000105572626000008 Input fundies:CapitalExpenditure: 487832 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1300377 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 84.95 million Exact value Exact value: -84945901 USD 2025-01-01 – 2025-12-31: -84945901 USD Inspect Net Income Open source Share or cite Citation for Net Income · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Net Income: -84945901 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -84945901 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1384295 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 88.63 million Exact value Exact value: -88629430 USD 2025-01-01 – 2025-12-31: -88629430 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Operating Cash Flow: -88629430 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88629430 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1293211 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.	USD 285,698 Exact value Exact value: 285698 USD 2025-01-01 – 2025-12-31: 285698 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Capital Expenditure: 285698 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 285698 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1299787 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.	−USD 88.92 million Calculation and evidence -88629430 − 285698 USD Exact free cash flow: -88915128 USD 2025-01-01 – 2025-12-31: -88629430 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 285698 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INOVIO PHARMACEUTICALS, INC. · 2025-12-31 INOVIO PHARMACEUTICALS, INC. (edgar:1055726) Free cash flow: -88915128 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:04:56Z Snapshot: d1d1b7508459bd4eaaf5ff41de9ebc54050a9e412500bbb561bc1eb43c65672c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1055726?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88629430 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1293211 Filing: 000105572626000008 Input fundies:CapitalExpenditure: 285698 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm#1299787 Filing: 000105572626000008 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

190 filings · 5,022 latest values · 5,022 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001055726, 1055726, INO, edgar:1055726

Also known as GENETRONICS BIOMEDICAL CORP, GENETRONICS BIOMEDICAL LTD, INOVIO BIOMEDICAL CORP, INOVIO PHARMACEUTICALS, INC., Inovio Pharmaceuticals, Inc.

INOVIO PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation